Eledon Pharmaceuticals, Inc. Common Stock ELDN
i
Market datapartial · fetched 2026-11-12T02:41:20.929Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:24:17.065608516Z
FundamentalsAlpha Vantage · unavailable
Eledon Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 6.30 | 294.7% | 138.0% | |||
| 25Δ | 5.91 | 277.7% | 124.0% | |||
| 30Δ | 5.51 | 260.8% | 110.1% | |||
| 35Δ | 5.11 | 243.8% | 96.2% | 2.51 | 276.6% | 20.0% |
| 40Δ | 4.71 | 226.8% | 82.3% | 2.95 | 286.5% | 18.4% |
| 45Δ | 4.31 | 209.9% | 68.3% | 3.39 | 296.4% | 16.8% |
| 50Δ | 3.91 | 192.9% | 54.4% | 3.82 | 306.3% | 15.2% |
| 55Δ | 3.51 | 176.0% | 40.5% | 4.26 | 316.3% | 13.5% |
| 60Δ | 3.12 | 159.0% | 26.5% | 4.70 | 326.2% | 11.9% |
| 65Δ | 2.72 | 142.0% | 12.6% | 5.14 | 336.1% | 10.3% |
| 70Δ | 2.42 | 154.1% | 5.0% | 5.58 | 346.0% | 8.6% |
| 75Δ | 2.25 | 201.1% | 5.0% | 6.02 | 355.9% | 7.0% |
| 80Δ | 2.08 | 248.0% | 5.0% | 6.46 | 365.8% | 5.4% |
20Δ
- Pseudo strike
- 6.30
- IV
- 294.7%
- B/E move
- 138.0%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 5.91
- IV
- 277.7%
- B/E move
- 124.0%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 5.51
- IV
- 260.8%
- B/E move
- 110.1%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 5.11
- IV
- 243.8%
- B/E move
- 96.2%
- Pseudo strike
- 2.51
- IV
- 276.6%
- B/E move
- 20.0%
40Δ
- Pseudo strike
- 4.71
- IV
- 226.8%
- B/E move
- 82.3%
- Pseudo strike
- 2.95
- IV
- 286.5%
- B/E move
- 18.4%
45Δ
- Pseudo strike
- 4.31
- IV
- 209.9%
- B/E move
- 68.3%
- Pseudo strike
- 3.39
- IV
- 296.4%
- B/E move
- 16.8%
50Δ
- Pseudo strike
- 3.91
- IV
- 192.9%
- B/E move
- 54.4%
- Pseudo strike
- 3.82
- IV
- 306.3%
- B/E move
- 15.2%
55Δ
- Pseudo strike
- 3.51
- IV
- 176.0%
- B/E move
- 40.5%
- Pseudo strike
- 4.26
- IV
- 316.3%
- B/E move
- 13.5%
60Δ
- Pseudo strike
- 3.12
- IV
- 159.0%
- B/E move
- 26.5%
- Pseudo strike
- 4.70
- IV
- 326.2%
- B/E move
- 11.9%
65Δ
- Pseudo strike
- 2.72
- IV
- 142.0%
- B/E move
- 12.6%
- Pseudo strike
- 5.14
- IV
- 336.1%
- B/E move
- 10.3%
70Δ
- Pseudo strike
- 2.42
- IV
- 154.1%
- B/E move
- 5.0%
- Pseudo strike
- 5.58
- IV
- 346.0%
- B/E move
- 8.6%
75Δ
- Pseudo strike
- 2.25
- IV
- 201.1%
- B/E move
- 5.0%
- Pseudo strike
- 6.02
- IV
- 355.9%
- B/E move
- 7.0%
80Δ
- Pseudo strike
- 2.08
- IV
- 248.0%
- B/E move
- 5.0%
- Pseudo strike
- 6.46
- IV
- 365.8%
- B/E move
- 5.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 105.57% | |
| 150.61% | |
| 193.14% | |
| 130.66% | |
| 118.12% | |
| 120.56% | |
| 113.59% | |
| 111.09% |
Biotechnology
ELTX
Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. Its lead product candidate, Eli-002,…
More →ELVN
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare challenges through its…
More →ENGN
enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to…
More →ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is…
More →ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical…
More →ERAS
Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers, aiming to meet significant unmet needs in…
More →